Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10537409
Filing Date		2005-11-25
First Named Inventor	Myun	g-Gyu PARK
Art Unit		1621
Examiner Name		
Attornov Docket Numb	or	CMT-0020

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant Rei				Lines where ges or Relev		
	1	4599152		1986-07	-08	Ashmead						
	2	6458981	B1	2002-10	L-01	Ashmead et al	ı					
	3 4830716 1989-05-16 Ashmead											
If you wish	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	Name of Patentee or Applicant of cited Document				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
If you wish	h to a	dd additional U.S. Publi:	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		_	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		_	
Examiner Initial*	Examiner Cite Foreign Document Country Number 3 Code 2 i Code						Name of Patente Applicant of cited Document	e or v	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
					-		1					

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10537409				
Filing Date		2005-11-25				
First Named Inventor	Myun	g-Gyu PARK				
Art Unit		1621				
Examiner Name						
Attorney Docket Numb	er	CMT-0020				

If you wish	h to a	dd add	ditie	onal F	oreig	n Pa	tent	Docu	ımer	nt cit	tation	n info	ormati	on pleas	se click t	he Add	button		Add			
							N	ON-F	PATI	ENT	LITE	ERA	TURE	DOCU	MENTS			R	emov	9		
Examinor Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisherd.									ТБ													
1 International Search Report, International Application No. PCT/RR20030002674; Date of Actual Completion March 2004; Date of Mailing March 16, 2004; 2 pages							larch 15,															
If you wisl	If you wish to add additional non-patent literature document citation information please click the Add button Add																					
	EXAMINER SIGNATURE																					
Examiner	Examiner Signature Date Considered																					
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a																					

I See Kint Code of USPTO Platent Documents at year, USPTO_GDUY on MEPD 910.6. Fights office that issued the document, by the two-leter code (WIPD Standard 913.). Fire Liganese patient documents, the inclusion to the year of the engin of the Emperor may precise the serial number of the patient document. If kind of document by the appropriate symbols as indicated on the document under WIPO Standard 51.16 if possible. Special register is required interesting the serial register is the patient document.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10537409				
Filing Date		2005-11-25				
First Named Inventor	Myun	g-Gyu PARK				
Art Unit		1621				
Examiner Name						
Attorney Docket Numb	er	CMT-0020				

CERTIFICATION STATEMENT

Please see 3	7 CFR	1.97 and	1.98 to make the	he appropriate selection(s);
--------------	-------	----------	------------------	------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) in

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David E. Rodrigues/	Date (YYYY-MM-DD)	2007-05-08
Name/Print	David F Rodrigues	Registration Number	50604

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.